S. C. Shapira

This study uses group activity monitoring in hamsters and mice to assess SARS-CoV-2 infection, convalescence, and vaccine efficacy.

This study evaluates the neutralization potency of four SARS-CoV-2 mAbs against spike mutations and two variants of concern, finding that MD65 and BL6 retain effectiveness against B.1.1.7 and B.1.351.

This study identifies and characterizes neutralizing antibodies targeting the SARS-CoV-2 spike N-terminal domain, showing their protective efficacy in mice.

This study shows that the human monoclonal antibody MD65 can rescue 100% of SARS-CoV-2 infected mice when administered up to 3 days post-exposure.

This study develops a recombinant VSV-ΔG-spike vaccine that provides single-dose protection against SARS-CoV-2 in hamsters by inducing neutralizing antibodies and preventing lung pathology.

This paper isolates and characterizes a panel of human neutralizing monoclonal antibodies targeting SARS-CoV-2 spike at multiple epitopes, suggesting their potential for combined post-exposure therapy.